"Bevacizumab" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An anti-VEGF recombinant monoclonal antibody consisting of humanized murine antibody. It inhibits VEGF RECEPTORS and helps prevent the proliferation of blood vessels.
Descriptor ID |
D000068258
|
MeSH Number(s) |
D12.776.124.486.485.114.224.060.375 D12.776.124.790.651.114.224.060.438 D12.776.377.715.548.114.224.200.438
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Bevacizumab".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Blood Proteins [D12.776.124]
- Immunoproteins [D12.776.124.486]
- Immunoglobulins [D12.776.124.486.485]
- Antibodies [D12.776.124.486.485.114]
- Antibodies, Monoclonal [D12.776.124.486.485.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.124.486.485.114.224.060]
- Bevacizumab [D12.776.124.486.485.114.224.060.375]
- Serum Globulins [D12.776.124.790]
- Immunoglobulins [D12.776.124.790.651]
- Antibodies [D12.776.124.790.651.114]
- Antibodies, Monoclonal [D12.776.124.790.651.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.124.790.651.114.224.060]
- Bevacizumab [D12.776.124.790.651.114.224.060.438]
- Globulins [D12.776.377]
- Serum Globulins [D12.776.377.715]
- Immunoglobulins [D12.776.377.715.548]
- Antibodies [D12.776.377.715.548.114]
- Antibodies, Monoclonal [D12.776.377.715.548.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.377.715.548.114.224.200]
- Bevacizumab [D12.776.377.715.548.114.224.200.438]
Below are MeSH descriptors whose meaning is more specific than "Bevacizumab".
This graph shows the total number of publications written about "Bevacizumab" by people in this website by year, and whether "Bevacizumab" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2006 | 0 | 1 | 1 |
2010 | 0 | 1 | 1 |
2012 | 0 | 1 | 1 |
2014 | 0 | 1 | 1 |
2015 | 1 | 0 | 1 |
2018 | 0 | 1 | 1 |
2019 | 0 | 1 | 1 |
2020 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Bevacizumab" by people in Profiles.
-
A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial. Clin Cancer Res. 2020 04 15; 26(8):1896-1904.
-
Evaluation of soluble carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the geparquinto phase III neoadjuvant breast cancer trial. Int J Cancer. 2019 08 01; 145(3):857-868.
-
BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study. J Clin Oncol. 2018 08 01; 36(22):2281-2287.
-
Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQuinto study. Int J Cancer. 2015 Dec 15; 137(12):2981-8.
-
Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)?. Ann Oncol. 2014 Dec; 25(12):2363-2372.
-
Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med. 2012 Jan 26; 366(4):299-309.
-
Integrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GeparQuinto trial. Ann Oncol. 2011 Feb; 22(2):301-6.
-
[Requirements for the development of molecularly defined targeted therapy in oncology]. Med Klin (Munich). 2006 Aug 15; 101(8):617-23.